Navigation Links
Regenesis Biomedical Announces Additions to Board of Directors
Date:8/22/2008

Strengthens breadth of experience and business expertise

SCOTTSDALE, Ariz., Aug. 22 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical technology company that markets the Provant(R) Wound Therapy System, announced today the addition of two members to its Board of Directors. The two new directors are Peter G. Savas, Chairman and CEO of Alseres Pharmaceuticals, and Charles "Chuck" S. Lunden, a principal with Bederson and Company.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080422/LATU008)

Peter Savas serves as Chairman and Chief Executive Officer of Alseres Pharmaceuticals. Prior to joining Alseres, Peter was Chairman and Chief Executive Officer of Aderis Pharmaceuticals, where he completed a $45 million private placement, strengthened the Board of Directors, Scientific Advisory Board and management team and rationalized the company's new product development partnerships. Peter holds his Bachelor of Arts degree in chemistry from Syracuse University.

Chuck Lunden is a Principal with Bederson and Company, certified public accountant consultants who provide financial and accounting services. He has comprehensive experience in corporate valuation and financial, tax and corporate management services. His designations include Certified Public Accountant, Accredited in Business Valuations, Certified Fraud Examiner, Certified Management Accountant, Chartered Life Underwriter, and Fellow of the Life Management Institute. Chuck holds a Bachelor of Science degree in economics from the University of Pennsylvania's Wharton School of Business. He is a member of the Board of Directors of HealthCare Data Diagnostics, a Medicare data analysis firm specializing in fraud detection. He is also a Member of the Board of Directors of the Spanish Health Ministries Inc.

"We are pleased to welcome these outstanding individuals to our team," said Virginia Rybski, Acting President of Regenesis. "Regenesis continues to demonstrate impressive revenue growth, and the perspectives of these individuals will contribute to our ongoing business plan execution."

About the Provant Wound Therapy System

Provant uses pulsed-radio frequency energy (PRFE) to facilitate reduction of the pain and edema associated with post-operative superficial soft tissues.

About Regenesis Biomedical

Regenesis Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. Regenesis developed, patented, and now markets the Provant Wound Therapy System. Our customers include health care facilities, acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and wound care clinics.

Contact: Regenesis Biomedical, Inc.

Scott Robey, Vice President Marketing

http://www.regenesisbiomedical.com 480-970-4970


'/>"/>
SOURCE Regenesis Biomedical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medicare Exemplary Provider Accreditation Awarded to Regenesis Biomedical
2. Regenesis Biomedical Appoints Scientific Advisory Board Composed of Life Science and Electronics Experts
3. Advanced BioHealing and Regenesis Biomedical Form Co-Promotion Alliance for Dermagraft(R)
4. Regenesis Biomedical Advances Corporate Strategy by Appointing Vice President of Marketing
5. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
6. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target
7. ArunA Biomedical Names William T. Sharp President and Chief Executive Officer
8. Roche and Response Biomedical Corporation Aim to Reduce Vein-to-Brain Time with New Point-of-Care Cardiac Tests
9. Frontage Laboratories Completes Acquisition of Advanced Biomedical Research, Inc. (ABR)
10. HIPAA Privacy Rule Impedes Biomedical Research
11. Ten Latin American Scientists Named 2008 Pew Fellows in the Biomedical Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , ... April 27, 2016 , ... The Pittcon Organizing ... 2019. Chuck has been a volunteer member of Committee since 1987. Since then, ... board of directors and treasurer and was chairman for both the program and exposition ...
(Date:4/27/2016)... ... April 27, 2016 , ... ... to announce the appointment of John Tilton as Chief Commercial Officer.  Mr. Tilton ... one of the founding commercial leaders responsible for the commercialization of multiple orphan ...
(Date:4/27/2016)... ... April 27, 2016 , ... Global Stem Cells Group CEO ... is the founder of GSCG affiliate Kimera Labs in Miami. , In 2004, Ross ... stem cell transplantation for hematologic disorders and the suppression of graft vs. host disease ...
(Date:4/26/2016)... (PRWEB) , ... April 27, 2016 , ... ... of Lewis Roca Rothgerber Christie LLP as an associate in the firm’s Intellectual ... and international electrical, mechanical and electromechanical patent applications. He has an electrical engineering ...
Breaking Biology Technology:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
Breaking Biology News(10 mins):